A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications.
Phase of Trial: Phase III
Latest Information Update: 01 May 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 12 Jun 2012 QOL results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 08 Dec 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History